United States - English - NLM (National Library of Medicine)

zoetis inc. - toceranib phosphate (unii: 24f9pf7j3r) (toceranib - unii:59l7y0530c) - toceranib 10 mg - palladia tablets are indicated for the treatment of patnaik grade ii or iii, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs. do not use in dogs used for breeding, or for pregnant or lactating bitches (see clinical pharmacology ).

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - valsartan hydrochlorothiazide - film coated tablet - 160/25 mg/mg

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - valsartan hydrochlorothiazide - film coated tablet - 80/12.5 mg/mg

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - valsartan hydrochlorothiazide - film coated tablet - 160/12.5 mg/mg

United States - English - NLM (National Library of Medicine)

swedish orphan biovitrum ab (publ) - palifermin (unii: qms40680k6) (palifermin - unii:qms40680k6) - palifermin 6.25 mg in 1.2 ml - kepivance is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ who grade 3 mucositis in the majority of patients. kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ who grade 3 mucositis in the majority of patients. the safety and efficacy of kepivance have not been established in patients with non-hematologic malignancies )]. the safety and efficacy of kepivance have not been established in patients with non-hematologic malignancies

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Ireland - English - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - lamotrigine - tablet - 100 milligram(s) - lamotrigine